arrow_back Back to App

Biologics Competition Act: Study on Interchangeable Biologics Substitution

This act mandates a study to evaluate how to facilitate access to more affordable interchangeable biological products. The goal is to reduce barriers to their use, potentially leading to lower treatment costs for citizens and greater availability of important therapies. The study results will help standardize information on these substitutes.
Key points
Mandates a study to assess how differences in evaluation systems impact the availability of interchangeable biological products.
Aims to facilitate access to more affordable interchangeable biological products, potentially lowering treatment costs.
Requires updating the public list of drugs (the 'Purple Book') to better communicate information on interchangeable biologics.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1790
Sponsor: Rep. Miller-Meeks, Mariannette [R-IA-1]
Process start date: 2023-03-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Biologics Competition Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1790.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-24.

What are the main provisions?

Key points include:

  • Mandates a study to assess how differences in evaluation systems impact the availability of interchangeable biological products.
  • Aims to facilitate access to more affordable interchangeable biological products, potentially lowering treatment costs.
  • Requires updating the public list of drugs (the 'Purple Book') to better communicate information on interchangeable biologics.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Miller-Meeks, Mariannette [R-IA-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health